Adaptive Biotechnologies Corporation (ADPT) specializes in leveraging the power of the immune system to revolutionize healthcare. The company focuses on immunomics, studying the immune system’s genetic code to unlock insights into diseases. Using its proprietary technology, Adaptive creates groundbreaking diagnostics and therapeutics that aid in the early detection and treatment of conditions such as cancer, […]
Read MoreFeatured Content ADMA Biologics, Inc. (ADMA) is a biopharmaceutical company focused on developing and manufacturing plasma-derived therapies to treat immune deficiencies and infectious diseases. ADMA’s main products include intravenous immune globulin (IVIG) therapies, specifically designed to treat patients with primary immune deficiency diseases (PIDD) who need antibody support. These therapies help boost the immune system, […]
Read MoreFeatured Content Nurix Therapeutics, Inc. (NRIX) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases by harnessing the power of the ubiquitin-proteasome system. Founded in 2015 and headquartered in San Francisco, California, Nurix aims to advance the field of targeted protein degradation, a cutting-edge approach that allows for […]
Read MoreApellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem […]
Read MoreNo matter how much the world moves away from COVID-19, the truth is that it isn’t going away. The move by government entities as well as healthcare organizations around the world to “endemic” phase protocols doesn’t mean the disease has been eradicated. It really means that the disease is acknowledged as a permanent part of […]
Read MoreNo matter how tired we get of hearing about COVID-19, the truth is that it hasn’t gone away, and neither have the health concerns associated with it. There is no denying that ever since the virus found its way to American shores almost three years ago, a lot of media attention has been given to […]
Read MoreMarket conditions are Mildly bullish in a Bear Market as of 2022-11-28. This means traders and investors should consider trading with a Neutral or Bullish bias by buying stocks and setting tight stops. The rank of the Bear Market is -16.70 which indicates the current market conditions are Extreme, Risk of a reversal is high. […]
Read MoreAs recently as last summer, a lot of signs about the global pandemic seemed to suggest that the worst of the worst was over, and we could all finally begin to put COVID-19 concerns and commentary in the rear view. As new, even more contagious variants of the virus have emerged, however, it has become […]
Read MoreYears ago, as I began my career as an investor, I read a book by Peter Lynch. Mr. Lynch had made his name, and his fortune, as the manager of Fidelity’s flagship Magellan fund in the late 70’s and ’80’s, and his incredible performance was one of the big reasons Magellan, at the time, was […]
Read MoreAs recently as a few months ago, a lot of signs about the global pandemic seemed to suggest that the worst of the worst was over, and we could all finally begin to put COVID-19 concerns and commentary in the rear view. As contagious variants of the virus have emerged, however, it has become more […]
Read MoreFulcrum Therapeutics, Inc. (FULC) Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment […]
Read More